Stocktoria
NewAmsterdam Pharma Co N.V. NAMS
NewAmsterdam Pharma Co N.V. (NAMS) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $22.5M at a -905.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-30 | RBC Capital | Outperform (main) |
| 2026-02-19 | Guggenheim | Buy (main) |
| 2026-02-18 | Needham | Buy (main) |
| 2026-01-21 | RBC Capital | Outperform (main) |
| 2025-12-16 | Stifel | Buy (main) |
| 2025-12-02 | Goldman Sachs | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.767 |
| Retained earnings / assets | -0.991 |
| EBIT / assets | -0.293 |
| Equity / liabilities | 7.96 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | 2/9 | 8.19 | — | -50.6% |
| ALMS | ALUMIS INC. | 1/9 | -7.78 | — | — |
| SCYX | SCYNEXIS INC | 4/9 | -13.88 | — | — |
| TRDA | Entrada Therapeutics, Inc. | 2/9 | 4.24 | — | -87.9% |
| SLGL | Sol-Gel Technologies Ltd. | 5/9 | -19.59 | — | +68% |
| CELU | Celularity Inc | 1/9 | — | — | -51% |
| CUE | Cue Biopharma, Inc. | 4/9 | — | — | — |
About NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
FAQ
Is NAMS financially healthy?
NewAmsterdam Pharma Co N.V.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does NAMS pay a dividend?
No, NewAmsterdam Pharma Co N.V. does not currently pay a dividend.
How profitable is NAMS?
In FY2025, NewAmsterdam Pharma Co N.V. had a net margin of -905.7% and a return on equity of -29.8%.
What is the analyst price target for NAMS?
The average Wall-Street price target for NewAmsterdam Pharma Co N.V. is $49.47, about 77.8% above the recent price, from 14 analysts (consensus: strong buy).
Is NAMS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NewAmsterdam Pharma Co N.V.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.